Well Cell Global

What Well Cell Global does

Well Cell Global LLC is a privately held biotech healthcare organization headquartered in Houston, Texas, that develops and licenses Physiologic Insulin Resensitization® (PIR®), a physician-directed office-based protocol for treating metabolic disorders including insulin resistance, diabetes, neuropathy, kidney disease, and retinopathy. The PIR protocol uses insulin intravenously as a hormone communicator rather than as a symptom-suppressing drug, administered via an FDA-authorized infusion pump; PIR is itself investigational and is the subject of an ongoing FDA clinical study. The company's core technology is multi-patented in the United States and supported by an evidence base of 13 peer-reviewed publications with two randomized controlled trials underway, supplemented by reproducible licensee outcomes (e.g., a 76% improvement in at least one complication in a 60-patient Schull Institute retrospective; 91% of kidney function stabilized or improved in a 66-patient Island Doctors cohort).

Well Cell monetizes its IP through a licensing model rather than direct patient billing. Physicians, clinics, and healthcare institutions license the PIR protocol and equipment; licensees undergo qualification and Hormonal Specialized Training on Insulin Used as a Hormone Rather than a Drug®; the company additionally provides business advisory, strategic planning, and marketing services to licensees, with execution supported by downstream partners such as Learner Park Media (marketing/lead generation) and Quail Financial Solutions (licensee financing). Customer segments are vertical, with physicians and clinics as the primary commercial target, healthcare institutions as a secondary channel for collaborative research, and patients with metabolic disorders as the end beneficiary. The company maintains a Global Healthcare Network and reports domestic and international licensee affiliates.

Operationally, Well Cell is a small entity (6 reported employees) led by Founder/CEO Scott A. Hepford with a Chief Science Officer (Richard B. Marchase) and Chief Growth Officer (Glenn Massey), supported by a Medical & Scientific Advisory Board. Recent corporate actions include a strategic alliance with Insulinic LLC (November 2024), a new patent (March 2025), the DIABETES CENTER OF EXCELLENCE® program (May 2025), and a $16.8 million federal court judgment plus permanent injunction enforcing its IP (August 2025). No funding rounds, revenue figures, or institutional investors are disclosed in the source materials.

Name

Well Cell Global

Legal name

Well Cell Global LLC

Website

https://wellcellglobal.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Privately held biotech healthcare organization that develops and licenses the multi-patented Physiologic Insulin Resensitization (PIR) physician-directed protocol for metabolic disorders, serving licensed physicians, clinics, and healthcare institutions.

Ownership category

akta.pro rank

Product category

Metabolic Disorder Treatment

NAICS

Surgical and Medical Instrument Manufacturing (339112), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Insulin Pumps & Patch Pumps (HLAHAIAG)

akta.pro secondary industries

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL), Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)

Keywords

• Metabolic disorder treatment
• Insulin resensitization therapy
• Physician-directed protocols
• Clinical protocol licensing
• Biotech healthcare licensing

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. PIR Protocol Licensing: The company licenses its patented Physiologic Insulin Resensitization (PIR) treatment protocol and equipment to physicians for the care of metabolic disease. Licensing includes protocol access, physician qualification, and training components.
2. Hormonal Specialized Training: Specialized education programs on Insulin Used as a Hormone Rather than a Drug for licensees and their healthcare providers, providing training to deliver PIR under physician direction.
3. Business Advisory Services: Business management consulting, strategic planning, and marketing services provided to licensees and partners in the metabolic treatment profession.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Core offering

Well Cell Global develops and licenses the patented Physiologic Insulin Resensitization (PIR) protocol to physicians and clinics for the treatment of metabolic disorders such as insulin resistance, diabetes, neuropathy, and kidney disease. The offering combines a multi-patented office-based infusion protocol using an FDA-authorized pump, physician qualification and training, business advisory services, and clinical research support to licensees.

Product overview

Well Cell Global is a biotech healthcare organization offering a unified platform centered on Physiologic Insulin Resensitization® (PIR®), a patented physician-directed treatment protocol for metabolic disorders. The core PIR® product is complemented by licensing programs, hormonal specialized training, business advisory services, and a peer-reviewed evidence base. The company operates through licensing its protocol to physicians and clinics, providing training, clinical research support, and business consulting services to licensees.

Differentiator

Problem solved

Functional benefit

Brands

• Physiologic Insulin Resensitization (PIR): Patented treatment protocol for metabolic disorder using insulin as a hormone rather than a drug to reduce insulin resistance
• Glucose Metabolism Optimization
• DIABETES CENTER OF EXCELLENCE

Products and services

• PIR® Treatment (Office-based Protocol) Physician-directed, office-based protocol that uses insulin intravenously as a hormone communicator to help patients reduce insulin resistance and address metabolic disorders such as diabetes, neuropathy, kidney disease, and cognitive decline. Delivered through licensed physicians using an FDA-authorized infusion pump and FDA-approved insulin.
• PIR® Licensing Program Licensing arrangement granting physicians, clinics, and healthcare institutions access to the patented PIR protocol, associated equipment, and physician qualification pathways for treating metabolic disease in their own practices.
• Hormonal Specialized Training Specialized education and training program on the 'Insulin Used as a Hormone Rather than a Drug' approach, equipping licensees and their healthcare providers to deliver PIR under physician direction in clinical practice.
• Business & Advisory Services Management consulting, strategic planning, and marketing services delivered to PIR licensees and partners to support their metabolic treatment practices.
• Diabetes Center of Excellence® Branded diabetes treatment excellence initiative announced in May 2025, building on the PIR protocol to deliver specialized diabetes care through licensed providers.

Quantifiable outcome

• 76% of patients showed improvement in at least one complication (n=60 study)
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core and supporting.

• Insulinic LLCcoreStrategic or Co-development Partner · 1 November 2024Strategic alliance formed November 2024 to advance metabolic disorder programs. Combined effort to advance metabolic disorder treatment initiatives through collaborative development and program enhancement.
• Learner Park MediasupportingGTM or Marketing PartnerMarketing support partner for Well Cell licensees. Provides social media lead generation, automated lead/patient follow-up platform, and services for lead capture, patient generation, retention and reactivation. Many licensees use Learner Park Media for their clinics.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Bigfoot Biomedical: Developer of smart insulin pen and connected diabetes management systems targeting insulin-requiring patients. Comparable as an emerging player in connected insulin delivery and physician-channel diabetes care.
• Virta Health: Digital metabolic health company offering physician-directed diabetes reversal and insulin resistance treatment programs. Comparable as a physician-channel metabolic disease therapy provider pursuing similar outcomes via a different modality.
• Omada Health: Digital chronic care company with a metabolic and prediabetes/diabetes program sold through health plans and providers. Comparable as a physician- and payer-aligned provider of metabolic disease care programs.
• Beta Bionics: Developer of the iLet bionic pancreas, an automated insulin delivery system for Type 1 diabetes. Comparable as a newer pump-based therapy innovator pursuing physiologic insulin dosing, with overlapping patient population.

Broad incumbents

• Abbott Diabetes Care: Manufacturer of FreeStyle Libre CGM systems and broader diabetes diagnostics portfolio. Adjacent incumbent providing connected glucose monitoring data that supports insulin dosing decisions in pump-based metabolic care.
• Medtronic: Global medical device incumbent with a leading insulin pump portfolio (MiniMed) used in diabetes management. Comparable as an established provider of insulin pump-based therapies for metabolic disorders that Well Cell's PIR protocol complements.
• Dexcom: Leading continuous glucose monitor (CGM) manufacturer integrated with insulin pump ecosystems. Adjacent incumbent whose CGM/insulin dosing products are commonly used alongside pump therapies like PIR.

Direct peers

• Insulet Corporation: Maker of the Omnipod patch insulin pump, the closest direct peer in insulin pump delivery for diabetes care. Both companies commercialize insulin pump technology to physicians and patients for metabolic disorder treatment.
• Tandem Diabetes Care: Manufacturer of the t:slim X2 insulin pump with automated insulin delivery features targeting Type 1 and insulin-resistant diabetes patients. Comparable as a pump-based diabetes therapy provider competing for the same physician and patient channel.
• Insulinic LLC: Strategic alliance partner developing metabolic disorder programs with Well Cell. Directly comparable as a metabolic disorder therapy developer in an active collaboration that overlaps in patient population and modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/well_cell_
• Facebookfacebook.com/1Buxvgzdk6
• LinkedInlinkedin.com/company/well-cell-global
• Instagraminstagram.com/well.cell.global

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Well Cell Global